Time to finger point or fix? An invitation to join ongoing efforts to promote ethical authorship and other good publication practices

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 1084-1087

  Woolley, Karen L ^a,b   Gertel, Art ^c,d   Hamilton, Cindy W ^e,f   Jacobs, Adam ^g   Snyder, Gene P ^h  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^c Beardsworth Consulting Group Inc   (United States)

^d Centre for Innovation in Regulatory Science   (United Kingdom)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f Hamilton House   (United States)

^g Dianthus Medical Limited   (United Kingdom)

^h Navicom Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; ETHICS; FOREIGN WORKER; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; TRUST; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; DRUG INDUSTRY; HUMANS; PEER REVIEW; PUBLISHING;

EID: 84880051941     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1S178     Document Type: Article

References (24)

1. Woolley KL, Gertel A, Hamilton C, Jacobs A, Snyder G (GAPP). Don't be a fool-don't use fool's gold. Am J Med 2012;125:e21-2.
2. Flaherty DK. Ghost-and guest-authored pharmaceutical industry-sponsored studies: abuse of academic integrity, the peer review system, and public trust. Ann Pharmacother 2013;47:xxxx. doi: 10.1345/aph.1R691
3. Bauchner H, Fontanarosa PB. Restoring confidence in the pharmaceutical industry. JAMA 2013;309:607-9.
4. Committee on Publication Ethics. How to spot authorship problems. http://publicationethics.org/files/u2/04F_How_to_spot_author_problems.pdf (accessed 2012 Mar 9).
5. Woolley KL. Goodbye ghostwriters! How to work ethically and efficiently with professional medical writers. Chest 2006;130:921-3.
6. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials. gov: cross sectional study. BMJ 2012;344:d7373.
7. Ross JS, Tse T, Zarin DA, et al. Publication of NIH funded trials registered in ClinicalTrials. gov: cross sectional analysis. BMJ 2012;344: d7292.
8. Woolley KL, Gertel A, Hamilton C, Jacobs A, Snyder G (GAPP). Poor compliance with reporting research results-we know it's a problem. how do we fix it? Curr Med Res Opin 2012;28:1857-60.
9. Woolley KL, Lew RA, Stretton S, et al. Lack of involvement of medical writers and the pharmaceutical industry in publications retracted for misconduct: a systematic, controlled, retrospective study. Curr Med Res Opin 2011;27:1175-82.
10. International Federation of Pharmaceutical Manufacturers and Associations. Joint position on the publication of clinical trial results in the scientific literature. June 10, 2010. www.ifpma.org/clinicaltrials (accessed 2012 Mar 9).
11. World Medical Association. WMA Declaration of Helsinki-ethical principles for medical research involving humans. October 2008. www. wma.net/en/30publications/10policies/b3/ (accessed 19 May 2013).
12. International Federation of Pharmaceutical Manufacturers and Associations. Joint position on the disclosure of clinical trial information via clinical trial registries and databases. November 10, 2009. www.ifpma.org/ clinicaltrials (accessed 2012 Mar 9).
13. Graf C, Battisti WP, Bridges D, et al. Research methods & reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330.
14. American Medical Writers Association. Code of ethics. www.amwa.org/ default.asp?Mode=DirectoryDisplay&id=114 (accessed 2012 Mar 9).
15. Jacobs A, Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 2005;21:317-21.
16. International Society for Medical Publication Professionals. Code of ethics. http://www.ismpp.org/code-of-ethics2 (accessed 2012 Mar 9).
17. Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ 2011;343:d6128.
18. Jacobs A, Hamilton CW. Decreased evidence of ghostwriting in a 2008 vs 2005 survey of medical writers. Write Stuff 2009;18:118-23.
19. Hamilton CW, Jacobs A. Evidence of decreased ghostwriting in a series of three surveys of medical communicators conducted between 2005 and 2011 (abstract). AMWA J 2012;27:115.
20. World Association of Medical Editors. Policy Satetment: Ghost-writing initiated by commercial companies. www.wame.org/resources/policies#ghost (accessed 2013 Jun 16).
21. Jacobs A. Adherence to the CONSORT guideline in papers written by professional medical writers. Write Stuff 2010;19:196-200.
22. Bailey M. Science editing and its effect on manuscript acceptance time. AMWA J 2011;26:147-52.
23. Gøtzsche PC, Kassirer JP, Woolley KL, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Med 2009;6:e23.
24. Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to publication among completed clinical trials. JAMA Intern Med 2013; 173:825-8.